It is designed to be administered by the patient at home and has the potential to dramatically change the treatment paradigm by enabling earlier non-invasive treatment to preserve vision and prevent progression, thereby delaying or completely eliminating the need for intravitreal injections and/or destructive laser procedures.

Phase 1b clinical trials of OTT166 eye drops have demonstrated safety, tolerability and clear clinical evidence of biological activity.

OTT166, has been studied in two separate multi-center, randomized, Phase 1b trials, in retinal disease patients and shown safety, tolerability and evidence of biological activity.

OcuTerra is currently studying the safety, efficacy and optimal dosing regimen of OTT166 through the Phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) study in patients with moderately-severe to severe non-proliferative and mild proliferative diabetic retinopathy.

Optical Coherence Tomography (OCT) images from 3 patients with Diabetic Macular Edema (DME) demonstrating Central Retinal Thickness (CRT) improvement and a clear biologic effect of topical OTT-166

	Central Retinal Thickness (CRT)µm
Patient	#103014		#107009		#103002
Baseline	530		766		404.5
Day 28	327.5	-202.5 (-38%)	570	-196 (-25%)	288.5	-116 (-29%)
Day 56	267	-263 (-50%)	577	-189 (-25%)	243.5	-161 (-40%)

Central Retinal Thickness (CRT)µm
Patient	#103014
Baseline	530
Day 28	327.5	-202.5 (-38%)
Day 267	267	-263 (-50%)
Patient	#107009
Baseline	766
Day 28	570	-196 (-25%)
Day 267	577	-189 (-25%)
Patient	#103002
Baseline	404.5
Day 28	288.5	-116 (-29%)
Day 267	243.5	-161 (-40%)

(note: central retinal thickness normal range: 260-280 µm)